| Not Yet Recruiting | Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis NCT04768777 | University of Alabama at Birmingham | N/A |
| Not Yet Recruiting | RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis NCT07006805 | Cabaletta Bio | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health E NCT07280871 | Luxembourg Institute of Health | — |
| Recruiting | Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis NCT06919900 | Georgia State University | N/A |
| Recruiting | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents NCT06408259 | Celgene | Phase 3 |
| Enrolling By Invitation | Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis NCT06495593 | University of California, San Francisco | Phase 4 |
| Recruiting | Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS NCT06390930 | Shirley Ryan AbilityLab | N/A |
| Active Not Recruiting | Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Mul NCT07235644 | Uppsala University | — |
| Recruiting | Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland) NCT06526364 | University Hospital, Basel, Switzerland | — |
| Active Not Recruiting | The Synergistic Effects of AIH and FES in Persons With MS NCT06413602 | Shirley Ryan AbilityLab | N/A |
| Recruiting | Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis NCT06569550 | Danish Research Centre for Magnetic Resonance | N/A |
| Recruiting | Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis NCT06389968 | Technical University of Munich | N/A |
| Active Not Recruiting | ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients NCT06345157 | Novartis Pharmaceuticals | — |
| Recruiting | Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis NCT06516458 | Shirley Ryan AbilityLab | — |
| Recruiting | Intermittent Hypoxia in Persons With Multiple Sclerosis NCT06276634 | Shirley Ryan AbilityLab | N/A |
| Unknown | the EXPOSITION Study NCT06325358 | University of Pavia | — |
| Recruiting | Multiple Sclerosis and the Effects of Ketogenic Diet Therapy NCT06715436 | IRCCS National Neurological Institute "C. Mondino" Foundation | N/A |
| Completed | A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data NCT06854341 | Novartis Pharmaceuticals | — |
| Unknown | Patient Experiences of Multiple Sclerosis (PExMS) NCT04236544 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Completed | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsi NCT06127095 | Biogen | — |
| Completed | A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumum NCT06897657 | Novartis Pharmaceuticals | — |
| Recruiting | Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimula NCT05958381 | The University of Texas at Dallas | N/A |
| Recruiting | Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on t NCT05920018 | Universität Münster | N/A |
| Recruiting | Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis NCT05964829 | Cionic, Inc. | N/A |
| Recruiting | Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands NCT06567197 | Amsterdam UMC, location VUmc | — |
| Recruiting | Biomarkers of aHSCT NCT06195800 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Recruiting | Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy NCT05359653 | University of California, San Francisco | Phase 1 / Phase 2 |
| Completed | A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in NCT05658601 | Bristol-Myers Squibb | — |
| Unknown | Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis NCT06303024 | Fondazione Don Carlo Gnocchi Onlus | N/A |
| Completed | the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosi NCT06129019 | Ataturk University | N/A |
| Recruiting | Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS NCT05834855 | Amsterdam UMC, location VUmc | Phase 3 |
| Completed | An Observational Biomarker Study in Multiple Sclerosis (MS) Patients NCT05663853 | LAPIX Therapeutics Inc. | — |
| Unknown | Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Scle NCT05615454 | Imam Abdulrahman Bin Faisal University | N/A |
| Active Not Recruiting | MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within th NCT06095271 | University Hospital, Basel, Switzerland | N/A |
| Unknown | Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis NCT05752630 | Hasselt University | — |
| Terminated | A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Nata NCT05532163 | Biogen | Phase 4 |
| Completed | The Effect of Task-Oriented Training and Virtual Reality Training on Balance, Gait and Fatigue in Individuals NCT07000968 | Inonu University | N/A |
| Enrolling By Invitation | Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administ NCT06223074 | Universidad Nacional Autonoma de Mexico | Phase 2 |
| Withdrawn | Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis NCT05482542 | Scripps Health | N/A |
| Completed | Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis NCT04972929 | University of Alabama at Birmingham | N/A |
| Unknown | The Relationships Between Personal Identity, Autobiographical Memory and Future Thinking in People With Multip NCT05648292 | Centre d'Investigation Clinique et Technologique 805 | — |
| Unknown | Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis NCT05519553 | Nantes University Hospital | N/A |
| Withdrawn | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis NCT04880577 | Massachusetts General Hospital | Phase 2 |
| Unknown | Cellular microRNA Signatures in Multiple Sclerosis NCT05290688 | Institut Pasteur | N/A |
| Unknown | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis NCT05340985 | Tehran University of Medical Sciences | Phase 4 |
| Completed | Effect of Computerized Cognitive Training in Persons With MS NCT05345288 | University of Nebraska | N/A |
| Unknown | Exercise Effects in Multiple Sclerosis NCT05496881 | University of Regina | N/A |
| Recruiting | Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns NCT05510817 | University Hospital of Mont-Godinne | N/A |
| Terminated | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab NCT05265728 | Biogen | Phase 3 |
| Unknown | B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis NCT05296161 | Amsterdam UMC, location VUmc | Phase 4 |
| Unknown | IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study NCT05417269 | Imcyse SA | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis NCT05168384 | Abu Dhabi Stem Cells Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy of Diet on Quality of Life in Multiple Sclerosis NCT05007483 | Terry L. Wahls | N/A |
| Active Not Recruiting | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Scleros NCT05201638 | Immunic AG | Phase 3 |
| Unknown | An Examination of Cognitive Fatigue Using Functional Neuroimaging NCT04885894 | Kessler Foundation | — |
| Recruiting | Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis NCT04458688 | Wayne State University | — |
| Recruiting | MS-ResearchBiomarkerS NCT05204459 | Cedars-Sinai Medical Center | — |
| Completed | Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosi NCT05028634 | Celgene | Phase 3 |
| Active Not Recruiting | A Post-Authorization, Long-term Study of Ozanimod Real-world Safety NCT05605782 | Bristol-Myers Squibb | — |
| Completed | Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis NCT04979650 | Mazandaran University of Medical Sciences | Phase 2 |
| Terminated | RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial NCT04625153 | RemeGen Co., Ltd. | Phase 2 |
| Unknown | Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI NCT04448977 | Kessler Foundation | — |
| Completed | Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden NCT05029206 | Uppsala University | — |
| Completed | Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta NCT04655222 | Biogen | — |
| Unknown | Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients NCT05902429 | Pontificia Universidade Católica do Rio Grande do Sul | Phase 4 |
| Unknown | Examining Effects of Tysabri on Cognitive Fatigue Using fMRI NCT04565431 | Kessler Foundation | — |
| Completed | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera NCT04756687 | Biogen | — |
| Completed | A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for P NCT05335031 | Bristol-Myers Squibb | — |
| Completed | Evaluation of Relapse Presence in Multiple Sclerosis NCT05218317 | Marmara University | — |
| Completed | Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their NCT04220814 | Rennes University Hospital | N/A |
| Completed | Speech in Noise Discrimination Skills in Multiple Sclerosis Patients. NCT06381297 | Asuman Kucukoner | N/A |
| Completed | Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis NCT05080270 | FibroBiologics | EARLY_Phase 1 |
| Completed | Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis NCT04528121 | Lama Saad El-Din Mahmoud | N/A |
| Completed | Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort NCT04580381 | University Hospital, Caen | — |
| Unknown | Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine NCT05019248 | Heinrich-Heine University, Duesseldorf | — |
| Completed | Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Sympt NCT04567264 | Chiara Zecca | N/A |
| Completed | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis NCT04261790 | Johns Hopkins University | Phase 4 |
| Active Not Recruiting | Calorie Restriction in Multiple Sclerosis NCT04042415 | Federico II University | N/A |
| Unknown | Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). NCT04260711 | Amsterdam UMC, location VUmc | N/A |
| Completed | The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Thre NCT04833673 | Hacettepe University | N/A |
| Completed | Delayed Diagnosis of Multiple Sclerosis, Treatment Initiation and Non-adherence in Upper Egypt NCT05438693 | doaa mokhtar mahmoud | — |
| Completed | Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis NCT04233970 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Completed | Phase II Clinical Trial of OCH-NCNP1 NCT04211740 | National Center of Neurology and Psychiatry, Japan | Phase 2 |
| Withdrawn | tDCS to Enhance Cognitive Training in Multiple Sclerosis NCT04261556 | University of Milano Bicocca | N/A |
| Recruiting | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Scler NCT03910738 | University Hospital, Strasbourg, France | Phase 2 |
| Completed | Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sc NCT03963375 | Washington University School of Medicine | Phase 4 |
| Completed | PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. NCT03942952 | University of Texas Southwestern Medical Center | — |
| Unknown | To Investigate the Effect of Aerobic Exercise on Neurophysiological Values and Functionality in Individuals Wi NCT04121637 | Firat University | N/A |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Par NCT03958877 | Biogen | Phase 3 |
| Completed | A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects NCT04121221 | Mapi Pharma Ltd. | Phase 3 |
| Completed | Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis NCT04002934 | Riley Bove, MD | Phase 2 |
| Unknown | Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis NCT04073940 | University of Illinois at Urbana-Champaign | N/A |
| Completed | Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Progr NCT04221191 | Biogen | — |
| Unknown | A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab NCT04048577 | Berkovich, Regina MD, PhD Inc. | Phase 4 |
| Completed | Cognition and MRI Markers in MS Patients With Aubagio® Treatment NCT03768648 | University Hospital, Bordeaux | N/A |
| Terminated | A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in P NCT03283397 | Bosnalijek D.D | Phase 3 |
| Terminated | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy NCT03870763 | Biogen | Phase 3 |
| Completed | Understanding Magnetic Resonance Imaging in Multiple Sclerosis NCT03872583 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Unknown | Sensitivity of Motor Assessment in MS - a Prospective Cohort Study NCT04993274 | Friedemann Paul | — |
| Active Not Recruiting | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS NCT03535298 | The Cleveland Clinic | Phase 4 |
| Completed | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RR NCT03689972 | Biogen | Phase 3 |
| Completed | The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis NCT03718026 | Gazi University | — |
| Completed | Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis NCT03975413 | Rush University Medical Center | — |
| Completed | Cortical Lesions in Patients With Multiple Sclerosis NCT03653585 | Danish Research Centre for Magnetic Resonance | — |
| Unknown | Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis NCT04450030 | University Hospital Muenster | — |
| Unknown | RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS NCT03979456 | Karolinska Institutet | Phase 3 |
| Completed | Acute Intermittent Hypoxia in Persons With Multiple Sclerosis NCT04280484 | Shirley Ryan AbilityLab | N/A |
| Unknown | Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis P NCT03610139 | American University of Beirut Medical Center | N/A |
| Active Not Recruiting | Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial NCT03500328 | Johns Hopkins University | N/A |
| Completed | Photobiomodulation Therapy in Persons With Multiple Sclerosis NCT03691766 | Marquette University | N/A |
| Unknown | Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis NCT03497468 | Bezmialem Vakif University | N/A |
| Terminated | A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS) NCT03387046 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Recruiting | Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis NCT03401879 | Medical University of Vienna | N/A |
| Completed | Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis NCT03385356 | University Medical Centre Maribor | Phase 4 |
| Completed | Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis NCT02988401 | Johns Hopkins University | Phase 1 / Phase 2 |
| Completed | A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis NCT03347370 | Biogen | — |
| Terminated | Maximizing Outcome of Multiple Sclerosis Transplantation NCT03342638 | Northwestern University | Phase 3 |
| Completed | Clinical Decision Support System (CADIMS) for MS Diagnostic NCT03205280 | Rennes University Hospital | — |
| Completed | Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of NCT02744222 | Biocad | Phase 2 / Phase 3 |
| Unknown | Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERV NCT02903537 | Fundació Institut Germans Trias i Pujol | Phase 1 |
| Completed | A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sc NCT05366036 | Eisai Korea Inc. | — |
| Terminated | Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients NCT03239860 | GeNeuro SA | Phase 2 |
| Terminated | Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate NCT02901106 | Fondation Ophtalmologique Adolphe de Rothschild | Phase 4 |
| Terminated | Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) NCT03126760 | Mallinckrodt ARD LLC | Phase 4 |
| Completed | Light Therapy as Treatment for Fatigue in Multiple Sclerosis NCT03060759 | Massachusetts General Hospital | N/A |
| Terminated | Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remit NCT03085810 | Hoffmann-La Roche | Phase 3 |
| Completed | Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) NCT03561402 | McGill University | — |
| Completed | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Subop NCT02861014 | Hoffmann-La Roche | Phase 3 |
| Completed | Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study NCT02914964 | Terry L. Wahls | N/A |
| Completed | Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis NCT03679806 | Dokuz Eylul University | N/A |
| Completed | RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. NCT02746744 | Anders Svenningsson | Phase 3 |
| Withdrawn | Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS NCT02675413 | Washington University School of Medicine | Phase 4 |
| Completed | Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS NCT02782858 | GeNeuro SA | Phase 2 |
| Completed | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) NCT02555215 | Biogen | Phase 3 |
| Completed | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Subop NCT02637856 | Genentech, Inc. | Phase 3 |
| Completed | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction NCT02652091 | Bayer | — |
| Completed | Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition NCT02598167 | Hoffmann-La Roche | — |
| Completed | Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse NCT02633033 | Mallinckrodt | — |
| Completed | Tecfidera and the Gut Microbiota NCT02471560 | Biogen | Phase 4 |
| Completed | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Mul NCT02545868 | Hoffmann-La Roche | Phase 3 |
| Completed | Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS NCT02410200 | Biogen | Phase 2 |
| Completed | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Scle NCT02525874 | Biogen | Phase 3 |
| Completed | Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) NCT02493049 | University of Calgary | Phase 2 |
| Completed | Open-label Study of Liothyronine in MS NCT02506751 | Johns Hopkins University | Phase 1 |
| Completed | Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential NCT02419378 | University Hospital Muenster | Phase 4 |
| Completed | ACTH for Fatigue in Multiple Sclerosis Patients NCT02315872 | Providence Health & Services | Phase 3 |
| Completed | Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Scle NCT02461069 | University Hospital Muenster | Phase 4 |
| Terminated | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive NCT02323269 | Biogen | — |
| Terminated | Oral Guanabenz for Multiple Sclerosis NCT02423083 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Unknown | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS NCT02587715 | Novo Cellular Medicine Institute LLP | Phase 1 / Phase 2 |
| Terminated | Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL) NCT02394782 | Merck KGaA, Darmstadt, Germany | — |
| Completed | This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) NCT02638038 | InteKrin Therapeutics, Inc. | Phase 2 |
| Unknown | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associa NCT02587806 | Novo Cellular Medicine Institute LLP | Phase 1 / Phase 2 |
| Completed | Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis NCT02403570 | Turku University Hospital | — |
| Terminated | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS NCT02418325 | Genesis Limited | Phase 1 / Phase 2 |
| Terminated | A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+ NCT02427776 | Imcyse SA | Phase 1 / Phase 2 |
| Unknown | DTI in Children With Multiple Sclerosis NCT02361697 | University Hospital Muenster | N/A |
| Unknown | Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis NCT02369926 | Transparency Life Sciences | Phase 2 |
| Completed | BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients NCT02247310 | Bayer | — |
| Terminated | Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis NCT02580669 | University Hospital, Montpellier | N/A |
| Withdrawn | Safety and Efficacy of Fingolimod in MS Patients in China NCT01941004 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis NCT02064816 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 NCT02579681 | Biogen | Phase 3 |
| Completed | Rebif® Rebidose® Versus Rebiject II® Ease-of-Use NCT02019550 | EMD Serono | Phase 4 |
| Completed | Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis NCT02040298 | University of California, San Francisco | Phase 2 |
| Completed | Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognit NCT05684016 | George Washington University | N/A |
| Completed | Measurement of Relaxin Peptide in Multiple Sclerosis (MS) NCT01909492 | Providence Health & Services | — |
| Terminated | A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of NCT01808482 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclero NCT01772199 | GlaxoSmithKline | Phase 2 |
| Completed | Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya NCT02137707 | McGill University | — |
| Completed | Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Scl NCT02687919 | Amanda Irish | N/A |
| Unknown | Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple NCT02769767 | Instituto Jalisciense de Cancerologia | — |
| Completed | Imaging of Intracerebral Inflammation in MS NCT02305264 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue o NCT01591551 | Cornerstone Health Care, PA | Phase 4 |
| Completed | Multiple Sclerosis and Progressive Resistance Training NCT01518660 | University of Aarhus | N/A |
| Completed | Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclero NCT02280876 | Universidad Austral de Chile | Phase 1 / Phase 2 |
| Completed | Worms for Immune Regulation of Multiple Sclerosis NCT01470521 | University of Nottingham | Phase 2 |
| Unknown | The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis NCT01453868 | Nelson Mandela Metropolitan University | EARLY_Phase 1 |
| Terminated | Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis NCT01435993 | GlaxoSmithKline | Phase 1 |
| Completed | Fingolimod -Response According to Coping - Evaluation NCT01420055 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients NCT01417312 | Charite University, Berlin, Germany | N/A |
| Completed | Healthy Volunteer Study Using 3 Different Formulations of Firategrast NCT01416363 | GlaxoSmithKline | Phase 1 |
| Withdrawn | QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® i NCT01071694 | Bayer | — |
| Completed | A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosph NCT01466322 | GlaxoSmithKline | Phase 1 |
| Completed | Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health NCT01667796 | Johns Hopkins University | N/A |
| Completed | An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients NCT01110993 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers NCT01431937 | GlaxoSmithKline | Phase 1 |
| Completed | Melatonin in Relapsing-Remitting Multiple Sclerosis Patients NCT01279876 | Tehran University of Medical Sciences | Phase 2 |
| Completed | A Cooperative Clinical Study of Abatacept in Multiple Sclerosis NCT01116427 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) NCT01143441 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 |
| Completed | Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How NCT01424462 | GlaxoSmithKline | Phase 1 |
| Completed | Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells NCT01414634 | Universitätsklinikum Hamburg-Eppendorf | Phase 1 / Phase 2 |
| Completed | An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Rel NCT01112345 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immu NCT01392872 | University Hospital, Clermont-Ferrand | N/A |
| Completed | Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple NCT02275741 | Dr. med. Micha Loebermann | — |
| Completed | An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in R NCT01108887 | Merck KGaA, Darmstadt, Germany | — |
| Completed | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuz NCT00930553 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Scler NCT01075880 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Bayer/Cognitive Assessments With Multiple Sclerosis Subjects NCT00888277 | University of Louisville | — |
| Completed | Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study NCT01628315 | University at Buffalo | — |
| Completed | Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS) NCT01080053 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) NCT01080027 | Merck KGaA, Darmstadt, Germany | — |
| Terminated | Rehabilitation Study in MS Patients NCT00780455 | Bayer | Phase 4 |
| Completed | To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients NCT01080040 | Merck KGaA, Darmstadt, Germany | — |
| Completed | A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Mul NCT01080001 | Merck KGaA, Darmstadt, Germany | — |
| Completed | A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis NCT00676715 | Genentech, Inc. | Phase 2 |
| Completed | COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS NCT00675883 | Biogen | — |
| Unknown | Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relaps NCT00984984 | Rennes University Hospital | Phase 3 |
| Terminated | Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis NCT00595920 | Opexa Therapeutics, Inc. | Phase 2 |
| Completed | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two NCT00548405 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One NCT00530348 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis NCT01158183 | Bayer | — |
| Completed | Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (M NCT00461396 | Bayer | — |
| Completed | BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose NCT00459667 | Bayer | Phase 3 |
| Unknown | Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis NCT00411723 | Artielle ImmunoTherapeutics | Phase 1 |
| Completed | A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis NCT00441103 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Completed | Differential Immune Effects of Natalizumab NCT00859482 | Cantonal Hospital of St. Gallen | — |
| Completed | A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis NCT01142583 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Phase I BP Interferon (IFN) Beta-004 NCT02517788 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Completed | Natalizumab Re-Initiation of Dosing NCT00306592 | Biogen | Phase 3 |
| Terminated | Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [ NCT01134627 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Completed | A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no NCT01142466 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and NCT01141751 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Phase I BP Interferon (IFN) Beta-001 NCT02515695 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Completed | A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) NCT00213135 | EMD Serono | Phase 3 |
| Completed | Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosi NCT01201343 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis NCT00097331 | GlaxoSmithKline | Phase 2 |
| Completed | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients NCT00099502 | Bayer | Phase 3 |
| Completed | Study Evaluating CCI-779 in Relapsing Multiple Sclerosis NCT00228397 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis NCT00071838 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability NCT00242177 | University of Illinois at Chicago | Phase 1 |
| Completed | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Scle NCT00276341 | Ipsen | Phase 3 |
| Completed | Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remi NCT00235989 | Bayer | Phase 2 |
| Completed | AVONEX® Combination Trial - "ACT" NCT00112034 | Biogen | Phase 4 |
| Completed | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosi NCT00097760 | Biogen | Phase 2 |
| Completed | An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS NCT00206648 | Bayer | Phase 4 |
| Completed | Safety of RG2077 in Patients With Multiple Sclerosis NCT00076934 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis NCT00220779 | Grifols Therapeutics LLC | Phase 2 |
| Completed | A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active NCT00050778 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis NCT00587691 | Opexa Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Treatment of Multiple Sclerosis Using Over the Counter Inosine NCT00067327 | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 |
| Completed | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis NCT00030966 | Biogen | Phase 3 |
| Completed | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis NCT00027300 | Biogen | Phase 3 |
| Completed | Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Scl NCT00292253 | EMD Serono | Phase 3 |
| Completed | A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) NCT00292266 | EMD Serono | Phase 3 |